AstraZeneca : Investor Day Biographies

Investor Day 2024

Unlocking growth to 2030 and beyond

Speaker biographies

Pascal Soriot

Chief Executive Officer

Pascal is Executive Director and Chief Executive Officer at AstraZeneca. He has been a member of the Board and CEO since October 2012. Pascal has a passion for science and medicine as well as a successful track record of managing change, executing strategy and leading a diverse organisation.

Prior to AstraZeneca, Pascal served as COO of Roche's pharmaceuticals division from 2010 to 2012 and previously as CEO of Genentech where he led its successful merger with Roche. Pascal joined the pharmaceutical industry in 1986 and has worked in senior roles in numerous major companies around the world. He is a Doctor of Veterinary Medicine and holds an MBA from HEC Paris.

Pascal received a British knighthood for services to life sciences and leadership in the global response to the COVID pandemic in the Queen's Birthday Honours 2022. He is also on the board of the Sustainable Markets Initiative and champions the Health Systems Task Force which aims to accelerate the delivery of net zero, sustainable healthcare.

Aradhana Sarin

Executive Director and Chief Financial Officer

Aradhana is Executive Director and Chief Financial Officer at AstraZeneca. She has been a member of the Board and CFO since August 2021.

Prior to her current role, Aradhana was CFO for Alexion. Aradhana joined Alexion in 2017 and was responsible for driving strategic growth, financial performance and business development at Alexion. She brings operational experience in biopharmaceuticals plus more than 20 years of professional experience at global financial institutions and has extensive knowledge of global healthcare systems, having closed more than 100 transactions across M&A, equity and debt financing.

Before joining Alexion, Aradhana was Managing Director of Healthcare Corporate and Investment Banking at Citi Global Banking, focusing on clients in the life sciences and biopharmaceutical sectors. Aradhana trained as a medical doctor in India and spent two years practising in both India and Africa. She completed her medical training at the University of Delhi and received her MBA from Stanford Business School.

Other appointments: Aradhana is on the Board of Governors of the American Red Cross and an independent director of Anheuser-Busch InBev.

Sharon Barr

Executive Vice President,

BioPharmaceuticals R&D

Sharon was appointed as Executive Vice-President, BioPharmaceuticals Research

• Development in August 2023. She is responsible for discovery through to late- stage development across CVRM and Respiratory & Immunology.

Prior to this role, Sharon served as Senior Vice President, Head of Research and Product Development of Alexion, AstraZeneca Rare Disease having joined in 2013. With more than 18 years of industry experience she has previously led translational research, precision medicines, and global drug development teams.

Sharon received her PhD in molecular biology from New York University, and completed a postdoctoral fellowship focused on mechanisms of DNA Damage and Repair at Stanford University.

In 2022, Sharon was recognised as a Healthcare Businesswoman's Association Luminary in recognition of her transformational leadership and passion for mentoring those around her.

Ruud Dobber

Executive Vice President and

President, BioPharmaceuticals

Ruud was appointed Executive Vice-President, BioPharmaceuticals Business Unit in January 2019 and is responsible for product strategy and commercial delivery for Cardiovascular, Renal and Metabolism, Respiratory and Immunology, and Vaccines & Immune Therapies. Prior to this, Ruud held the role of Executive Vice-President, North America and was responsible for driving growth and maximising the contribution of the commercial operations in North America.

Ruud joined Astra in 1997 and has assumed leadership roles with increasing responsibility including Executive Vice-President, North America; Executive Vice- President, Europe; Regional Vice-President, Europe, Middle East and Africa; and Regional Vice-President, Asia Pacific. Ruud served as a member of the board and executive committee of the European Federation of Pharmaceutical Industries and Associations and was previously Chairman of the Asia division of Pharmaceutical Research and Manufacturers of America. Ruud holds a doctorate in immunology from the University of Leiden, Netherlands, beginning his career as a research scientist in immunology and ageing.

Marc Dunoyer

Chief Executive Officer, Alexion and Chief Strategy Officer, AstraZeneca

Marc became Chief Executive Officer of Alexion, AstraZeneca's Rare Disease group, in August 2021 following its acquisition in July 2021. He had previously served as an Executive Director and AstraZeneca's Chief Financial Officer from November 2013.

Marc's career in pharmaceuticals, which has included periods with Roussel Uclaf, Hoechst Marion Roussel and GSK, has given him extensive industry experience. He is a qualified accountant and joined AstraZeneca in 2013, serving as Executive Vice-President, Global Product and Portfolio Strategy from June to October 2013. Prior to that, he served as Global Head of Rare Diseases at GSK and, concurrently, Chairman, GSK Japan.

He holds an MBA from HEC Paris and a Bachelor of Law degree from Paris University.

Dave Fredrickson

Executive Vice President, Oncology Business

Dave was appointed Executive Vice-President, Oncology Business Unit in October 2017 and is responsible for driving growth and maximising the global commercial performance of the AstraZeneca global Oncology portfolio.

Previously, Dave served as President of AstraZeneca Japan and Vice-President, Specialty Care in the US. While in Japan, Dave also served as Vice Chairman of the European Federation of Pharmaceutical Industries and Associations Japan and was a Director of the Japan Pharmaceutical Manufacturers Association.

Before joining AstraZeneca, Dave worked at Roche/Genentech, where he served in several functions and leadership positions. Prior to this, Dave worked at the Monitor Group, now Monitor Deloitte Group, a global strategy consultancy.

Dave is a graduate of Georgetown University in Washington DC.

Susan Galbraith

Executive Vice President, Oncology R&D

Susan was appointed as Executive Vice-President, Oncology Research & Development in July 2021, with responsibility for transforming the productivity and scientific output from Oncology R&D. Over her career, Susan has helped develop 12 approved medicines.

As a clinical oncologist, Susan studied medicine at Manchester and Cambridge Universities and has a PhD from the University of London. In recognition of her contributions to Oncology drug development, she has been awarded an honorary Doctorate of Medical Science from the Institute of Cancer Research, is a Fellow of the Academy of Medical Sciences and elected to the Academy of the American Association for Cancer Research.

Susan is a member of the Cambridge Cancer Centre Executive Committee and the Scientific Advisory Board of the ICR. From 2021 to 2024, she also served on the Board of Directors of the AACR and currently serves on the European Association of Cancer Research Advisory Council.

Iskra Reic

Executive Vice President, V&I

Iskra is an EVP for V&I, with responsibility across the pipeline and portfolio, including R&D, medical affairs, marketing, and commercial operations. In 2021, Iskra was appointed Head of the Vaccines & Immune Therapies division, and supported the delivery of over 3bn doses of our COVID-19 vaccine to 180 countries, as well as successfully bringing to market the first pre-exposure prophylaxis monoclonal antibody to protect immunocompromised patients.

Iskra is also the Senior Executive Team sponsor of the Partnership for Health System Sustainability and Resilience and represents AstraZeneca on the PHSSR Steering Committee alongside leaders from organisations such as the London School of Economics, the World Economic Forum and the WHO Foundation.

Iskra trained as a Doctor of dental medicine at the Medical University of Zagreb, Croatia, and has a PhD in Strategy and Leadership and an International Executive MBA in Business and Leadership from the IEDC-Bled School of Management, Slovenia.

Andrew Barnett

Vice President, Investor Relations

Andy is Head of Investor Relations at AstraZeneca. Andy joined AstraZeneca in 2019, initially as Global Head of Commercial for Immuno-Oncology, followed by Global Franchise Head for Lynparza, DDR and Established Oncology within the Oncology Business Unit.

Before joining AstraZeneca, Andy spent 11 years at Roche in roles of increasing responsibility. Most recently he was Head of Commercial for Asia Pacific. Prior to that, he worked in a variety of global and local country positions in Europe, US and Asia, including Lifecycle Leader and General Manager.

Andy holds a BSs(Hons) in Biochemistry from McGill University in Montreal and a Diploma in Marketing from the Chartered Institute of Marketing in the UK.